title: [Anagrelide in the treatment of essential thrombocythemia (ET) and other myeloproliferative disorders with thrombocythemia based on data from patient register in the CR].
abstract: Anagrelide hydrochloride is an effective drug used in patients with ET and other myeloproliferative disorders with thrombocythemia to selectively decrease the number of thrombocytes. Indications for use of anagrelide were described in detail in Czech medical literature. Since 2005 data concerning treatment with anagrelide in some medical clinics have been collected in patient register showing course of treatment from 2004, when the medicament obtained marketing authorization from State Institute for Drug Control to be used in the treatment of thrombocythemia in myeloproliferative disorders. Aim of patient register is to monitor medical effect of anagrelide therapy and incidence of adverse effects in patients with ET and other myeloproliferative disorders and subsequent analysis of collected data. At the moment patient register contains data from 154 patients.
authors.affiliation: Oddelení klinické hematologie FN Brno. m.penka@fnbrno.cz
authors.forename: M
authors.initials: M
authors.lastname: Penka
authors.forename: M
authors.initials: M
authors.lastname: Doubek
authors.forename: J
authors.initials: J
authors.lastname: Schwarz
authors.forename: R
authors.initials: R
authors.lastname: Pytlík
authors.forename: P
authors.initials: P
authors.lastname: Dulícek
authors.forename: J
authors.initials: J
authors.lastname: Kissová
authors.forename: A
authors.initials: A
authors.lastname: Hlusí
authors.forename: V
authors.initials: V
authors.lastname: Vozobulová
authors.forename: O
authors.initials: O
authors.lastname: Cerná
authors.forename: Y
authors.initials: Y
authors.lastname: Brychtová
authors.forename: T
authors.initials: T
authors.lastname: Szotkowski
authors.forename: Z
authors.initials: Z
authors.lastname: Volková
authors.forename: J
authors.initials: J
authors.lastname: Seghetová
authors.forename: M
authors.initials: M
authors.lastname: Schutzová
authors.forename: I
authors.initials: I
authors.lastname: Hadacová
authors.forename: I
authors.initials: I
authors.lastname: Hochová
authors.forename: J
authors.initials: J
authors.lastname: Voglová
authors.forename: O
authors.initials: O
authors.lastname: Siroký
authors.forename: D
authors.initials: D
authors.lastname: Belada
authors.forename: T
authors.initials: T
authors.lastname: Lhot'anová
authors.forename: B
authors.initials: B
authors.lastname: Bubeník
authors.forename: M
authors.initials: M
authors.lastname: Vránová
authors.forename: M
authors.initials: M
authors.lastname: Micaníková
authors.forename: L
authors.initials: L
authors.lastname: Dusek
mesh_terms: D006801:Humans; D009196:Myeloproliferative Disorders / Q000150:complications*; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D011799:Quinazolines / Q000009:adverse effects / Q000627:therapeutic use*; D013920:Thrombocythemia, Essential / Q000188:drug therapy*; D013922:Thrombocytosis / Q000150:complications / Q000188:drug therapy*
chemical_list: D010975:Platelet Aggregation Inhibitors; D011799:Quinazolines; C021139:anagrelide